Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.vaccine.2021.01.044 http://scihub22266oqcxt.onion/10.1016/j.vaccine.2021.01.044 33516600!7816590!33516600     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Vaccine 2021 ; 39 (8): 1241-1247 Nephropedia Template TP {{tp|p=33516600|t=2021. Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response |pdf=|usr=}}{{33516600}} gab.com Text Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response JO: Vaccine http://www.kidney.de/pget.php?&tw=1&pmid=33516600 #FOAvip Without approved vaccines and specific treatments, COVID-19 is spreading around the world with above 26 million cases and approximately 864 thousand deaths until now. An efficacious and affordable vaccine is urgently needed. The Val308 - Gly548 of spike protein of SARS-CoV-2 linked with Gln830 - Glu843 of Tetanus toxoid (TT peptide) (designated as S1-4) and without TT peptide (designated as S1-5) were expressed and renatured. The antigenicity and immunogenicity of S1-4 were evaluated by Western Blotting (WB) in vitro and immune responses in mice, respectively. The protective efficiency was measured preliminarily by microneutralization assay (MN50). The soluble S1-4 and S1-5 protein was prepared to high homogeneity and purity. Adjuvanted with Alum, S1-4 protein stimulated a strong antibody response in immunized mice and caused a major Th2-type cellular immunity supplemented with Th1-type immunity. Furthermore, the immunized sera could protect the Vero E6 cells from SARS-CoV-2 infection with neutralizing antibody titer 256. Recombinant SARS-CoV-2 RBD with a built in T helper epitope could stimulate both strong humoral immunity supplemented with cellular immunity in mice, demonstrating that it could be a promising subunit vaccine candidate. Twit Text FOAVip Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response ????Vaccine http://www.kidney.de/pget.php?&tw=1&pmid=33516600 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33516600 #FOAvip English Wikipedia <ref>{{Cite pmid|33516600}}</ref> Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response #MMPMID33516600 Su QD; Zou YN; Yi Y; Shen LP; Ye XZ; Zhang Y; Wang H; Ke H; Song JD; Hu KP; Cheng BL; Qiu F; Yu PC; Zhou WT; Zhao R; Cao L; Dong GF; Bi SL; Wu GZ; Gao GF; Zheng J Vaccine 2021[Feb]; 39 (8): 1241-1247 PMID33516600show ga Without approved vaccines and specific treatments, COVID-19 is spreading around the world with above 26 million cases and approximately 864 thousand deaths until now. An efficacious and affordable vaccine is urgently needed. The Val308 - Gly548 of spike protein of SARS-CoV-2 linked with Gln830 - Glu843 of Tetanus toxoid (TT peptide) (designated as S1-4) and without TT peptide (designated as S1-5) were expressed and renatured. The antigenicity and immunogenicity of S1-4 were evaluated by Western Blotting (WB) in vitro and immune responses in mice, respectively. The protective efficiency was measured preliminarily by microneutralization assay (MN50). The soluble S1-4 and S1-5 protein was prepared to high homogeneity and purity. Adjuvanted with Alum, S1-4 protein stimulated a strong antibody response in immunized mice and caused a major Th2-type cellular immunity supplemented with Th1-type immunity. Furthermore, the immunized sera could protect the Vero E6 cells from SARS-CoV-2 infection with neutralizing antibody titer 256. Recombinant SARS-CoV-2 RBD with a built in T helper epitope could stimulate both strong humoral immunity supplemented with cellular immunity in mice, demonstrating that it could be a promising subunit vaccine candidate. |Animals[MESH] |Antibodies, Neutralizing/immunology[MESH] |Antibodies, Viral/*immunology[MESH] |Antibody Formation[MESH] |COVID-19[MESH] |COVID-19 Vaccines/*immunology[MESH] |Epitopes, T-Lymphocyte/*immunology[MESH] |Female[MESH] |Humans[MESH] |Mice[MESH] |Mice, Inbred BALB C[MESH] |SARS-CoV-2[MESH]Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces st(epmc).pdf DeepDyve Pubget Overpricing